EP1052998A4 - Zusammensetzungen und verfahren zur modulierung von cytokin freisetzung erzeugt durch genotoxische mitteln - Google Patents

Zusammensetzungen und verfahren zur modulierung von cytokin freisetzung erzeugt durch genotoxische mitteln

Info

Publication number
EP1052998A4
EP1052998A4 EP99904568A EP99904568A EP1052998A4 EP 1052998 A4 EP1052998 A4 EP 1052998A4 EP 99904568 A EP99904568 A EP 99904568A EP 99904568 A EP99904568 A EP 99904568A EP 1052998 A4 EP1052998 A4 EP 1052998A4
Authority
EP
European Patent Office
Prior art keywords
dna
protein kinase
agent
genotoxic
kinase inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99904568A
Other languages
English (en)
French (fr)
Other versions
EP1052998A1 (de
Inventor
Daniel B Yarosh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Applied Genetics Inc
Original Assignee
Applied Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Genetics Inc filed Critical Applied Genetics Inc
Publication of EP1052998A1 publication Critical patent/EP1052998A1/de
Publication of EP1052998A4 publication Critical patent/EP1052998A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
EP99904568A 1998-02-04 1999-02-04 Zusammensetzungen und verfahren zur modulierung von cytokin freisetzung erzeugt durch genotoxische mitteln Withdrawn EP1052998A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7364098P 1998-02-04 1998-02-04
US73640P 1998-02-04
PCT/US1999/002348 WO1999039720A1 (en) 1998-02-04 1999-02-04 Compositions and methods for modulating cytokine release in response to genotoxic agents

Publications (2)

Publication Number Publication Date
EP1052998A1 EP1052998A1 (de) 2000-11-22
EP1052998A4 true EP1052998A4 (de) 2003-02-26

Family

ID=22114913

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99904568A Withdrawn EP1052998A4 (de) 1998-02-04 1999-02-04 Zusammensetzungen und verfahren zur modulierung von cytokin freisetzung erzeugt durch genotoxische mitteln

Country Status (7)

Country Link
EP (1) EP1052998A4 (de)
JP (1) JP2002502820A (de)
CN (1) CN1296413A (de)
AU (1) AU2494499A (de)
CA (1) CA2319567A1 (de)
IL (1) IL137253A0 (de)
WO (1) WO1999039720A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070032853A1 (en) 2002-03-27 2007-02-08 Hossainy Syed F 40-O-(2-hydroxy)ethyl-rapamycin coated stent
US20050118344A1 (en) 2003-12-01 2005-06-02 Pacetti Stephen D. Temperature controlled crimping

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0525960A1 (de) * 1991-06-18 1993-02-03 American Home Products Corporation Verwendung von Rapamycin zur Behandlung von T-Zellen Lymphom/Leukämie bei Erwachsenen

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0525960A1 (de) * 1991-06-18 1993-02-03 American Home Products Corporation Verwendung von Rapamycin zur Behandlung von T-Zellen Lymphom/Leukämie bei Erwachsenen

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BASU S ET AL: "The DNA-dependent protein kinase participates in the activation of NF kappa B following DNA damage.", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS. UNITED STATES 9 JUN 1998, vol. 247, no. 1, 9 June 1998 (1998-06-09), pages 79 - 83, XP001097650, ISSN: 0006-291X *
HOSOI Y ET AL: "A phosphatidylinositol 3-kinase inhibitor wortmannin induces radioresistant DNA synthesis and sensitizes cells to bleomycin and ionizing radiation.", INTERNATIONAL JOURNAL OF CANCER. JOURNAL INTERNATIONAL DU CANCER. UNITED STATES 23 NOV 1998, vol. 78, no. 5, 23 November 1998 (1998-11-23), pages 642 - 647, XP002919460, ISSN: 0020-7136 *
MOLNAR-KIMBER K L ET AL: "Comparison of effects of sirolimus on cytokine dependent and cytokine independent proliferation.", INFLAMMATION RESEARCH: OFFICIAL JOURNAL OF THE EUROPEAN HISTAMINE RESEARCH SOCIETY... [ET AL.]. SWITZERLAND AUG 1995, vol. 44 Suppl 2, August 1995 (1995-08-01), pages S189 - S190, XP001070575, ISSN: 1023-3830 *
ROSENZWEIG K E ET AL: "Radiosensitization of human tumor cells by the phosphatidylinositol3-kinase inhibitors wortmannin and LY294002 correlates with inhibition of DNA-dependent protein kinase and prolonged G2-M delay.", CLINICAL CANCER RESEARCH: AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH. UNITED STATES JUL 1997, vol. 3, no. 7, July 1997 (1997-07-01), pages 1149 - 1156, XP001069065, ISSN: 1078-0432 *
See also references of WO9939720A1 *

Also Published As

Publication number Publication date
CA2319567A1 (en) 1999-08-12
EP1052998A1 (de) 2000-11-22
AU2494499A (en) 1999-08-23
WO1999039720A1 (en) 1999-08-12
IL137253A0 (en) 2001-07-24
CN1296413A (zh) 2001-05-23
JP2002502820A (ja) 2002-01-29

Similar Documents

Publication Publication Date Title
Kharbanda et al. Activation of the c-Abl tyrosine kinase in the stress response to DMA-damaging agents
Liu et al. A novel poly (ADP-ribose) polymerase inhibitor, ABT-888, radiosensitizes malignant human cell lines under hypoxia
Abeyama et al. A role for NF-κB–dependent gene transactivation in sunburn
Oliver et al. Drug resistance in glioblastoma: are persisters the key to therapy?
Luo et al. Redox regulation of DNA repair: implications for human health and cancer therapeutic development
US7414020B2 (en) Human checkpoint kinase, hCDS1, compositions and methods
HU229263B1 (en) The use of pharmaceutical compositions containing 4-h-1-benzopyran-4-one derivatives as inhibitors of smooth muscle cell proliferation
Hou et al. mTOR inhibitor rapamycin alone or combined with cisplatin inhibits growth of esophageal squamous cell carcinoma in nude mice
Little et al. Focus: skin: cutaneous lupus erythematosus: current and future pathogenesis-directed therapies
Windhofer et al. Marked dependence on growth state of backup pathways of NHEJ
Habib et al. Novel mechanism of reducing tumourigenesis: upregulation of the DNA repair enzyme OGG1 by rapamycin-mediated AMPK activation and mTOR inhibition
Rather et al. Oncogenic BRAF, endoplasmic reticulum stress, and autophagy: Crosstalk and therapeutic targets in cutaneous melanoma
Sabi et al. Elucidating the role of hypoxia-inducible factor in rheumatoid arthritis
WO2007143629A1 (en) Treatment of neurofibromatosis with inhibitors of a signal transduction pathway
Chen et al. The different biological effects of TMPyP4 and cisplatin in the inflammatory microenvironment of osteosarcoma are attributed to G‐quadruplex
Booth et al. NEDD4 over-expression regulates the afatinib resistant phenotype of NSCLC cells
Nandi et al. YY1 control of mitochondrial‐related genes does not account for regulation of immunoglobulin class switch recombination in mice
WO1999039720A1 (en) Compositions and methods for modulating cytokine release in response to genotoxic agents
Enns et al. Effects of the protein kinase inhibitors wortmannin and KN62 on cellular radiosensitivity and radiation-activated S phase and G1/S checkpoints in normal human fibroblasts
Gordon et al. A role for molecular radiobiology in radiotherapy?
Zhao et al. OGG1 in the kidney: beyond Base Excision Repair
WO1997008184A1 (en) Methods and compositions including dna damaging agents and tyrosine kinase inhibitors or activators
Maeda et al. Sulfoquinovosyl acylpropanediol (SQAP): Inhibition of poly (ADP-ribose) metabolism and enhanced cytotoxicity in homologous recombination repair-deficient Chinese hamster-derived cells
Athans The Effect of Solar Ultraviolet Induced Activation of Constitutive Nitric Oxide Synthase on Primary Fibroblast Cells
Guo Hypersensitivity of BRCA-Deficient Cancer Cells to FEN1 Inhibition

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000714

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): DE ES FR GB IT

RIC1 Information provided on ipc code assigned before grant

Free format text: 7A 61K 31/436 A, 7A 61K 31/70 B, 7A 61K 7/40 B, 7A 61K 7/42 B, 7A 61K 38/43 B, 7A 61P 35/00 B

RIC1 Information provided on ipc code assigned before grant

Free format text: 7A 61K 31/436 A, 7A 61K 31/70 B, 7A 61K 7/40 B, 7A 61K 7/42 B, 7A 61K 38/43 B, 7A 61P 35/00 B, 7A 61K 31/435 B

A4 Supplementary search report drawn up and despatched

Effective date: 20030114

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20030411